Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Category: #health  By Paroma Bhattacharya  Date: 2019-10-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Nature Tech Corp partners with Aldevron for gene therapy manufacturing

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and pharmaceutical firms in the field are increasingly forging collaborations and partnerships.

Aldevron, a US-based biotechnology company focused on the creation of plasmids, RNA as well as gene-editing enzymes used by pharmaceutical firms in clinical trials, reportedly announced a new licensing partnership agreement with the Nebraska-based Nature Technology Corporation (NTC).

The company announced the instant availability of antibiotic-free RNA-OUT and Nanoplasmids™ technology for utilization in gene therapy manufacturing.

Aldevron can now offer its clients the option of utilizing the plasmid technology of NTC to facilitate a more efficient system for producing viral vectors that are used in cell and gene therapy. Furthermore, gene and cell therapy firms keen to use NTC’s technology can now directly go to Aldevron for their production needs without obtaining a license from NTC first.

CEO at Aldevron, Michael Chambers stated that researchers of gene and cell therapy continue to make amazing discoveries that would improve lives for several millions of people.

Chambers further added that the company is committed to offering the best production technologies to support breakthrough treatments. The company’s partnership with NTC allows the company to offer plasmid technology that immensely improves the manufacturing procedure and decreases regulatory risk, which further results in a faster time and reduced costs to patients.

The domains of gene and cell therapy are growing with the approvals of Yescarta™ and Kymriah™ CAR-T cancer treatments and Luxturna™ to treat a rare genetic ocular disease, Leber congenital amaurosis. With around 3,000 clinical studies underway, enhancements in manufacturing are needed to provide the capacity for growth accommodation in research as well as anticipated commercial products.

The NTC technology, coupled with the unequaled throughput and scale of Aldevron, assure users will get the products they require.

CEO of NTC, Clague Hodgson stated that the company’s RNA-OUT and Nanoplasmid technology has been under development for 12 years, showcasing demonstrable advantages for the manufacturing of viral vectors.

Hodgson added that the company is thrilled to partner with Aldevron to further make this amazing technology immediately available to its customers so that they could avoid the expense and delay associated with licensing procedures, thereby removing the barriers to delivering transformative therapies to patients.

 

Source credit: https://www.globenewswire.com/news-release/2019/10/22/1932931/0/en/Aldevron-Nature-Technology-Corporation-team-up-to-offer-Nanoplasmids-for-gene-therapy-manufacturing.html



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Genentech IMbrave150 study meets coprimary endpoints for HCC treatment
Genentech IMbrave150 study meets coprimary endpoints for HCC treatment
By Paroma Bhattacharya

With growing occurrence of liver cancer cases across the globe, the need to find a solution to the ailment is rising steadily among global biotechnology and pharmaceutical firms. Various clinical trials and studies are...